APGE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
96.0M
+16.0%
82.8M
+6.0%
78.1M
+9.5%
71.3M
-2.6%
73.2M
R&D
67.3M
+10.7%
60.8M
+4.1%
58.4M
+7.9%
54.2M
-2.7%
55.7M
SG&A
24.3M
+10.9%
22.0M
+11.9%
19.6M
+14.7%
17.1M
-2.1%
17.5M
Operating Income
-96004000
-16.0%
-82772000
-6.0%
-78056000
-9.5%
-71278000
+2.6%
-73165000
EBITDA
-91234000
-10.8%
-82364000
-6.1%
-77650000
-9.6%
-70872000
+2.6%
-72766000
Net Income
-85854000
-15.8%
-74111000
-6.8%
-69387000
-6.7%
-65021000
+1.6%
-66096000
EPS (Basic)
$-1.14
-7.5%
$-1.06
-2.9%
$-1.03
+7.2%
$-1.11
+1.8%
$-1.13
EPS (Diluted)
$-1.14
-7.5%
$-1.06
-2.9%
$-1.03
+7.2%
$-1.11
+1.8%
$-1.13
Shares (Diluted)
75.4M
+8.3%
69.7M
+3.4%
67.4M
+14.6%
58.8M
+0.6%
58.4M
Apogee Therapeutics (APGE) โ€” Financials